News

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
Key Takeaways BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker ...
Just two days after retiring the entirety of the US Centers for Disease Control and Prevention’s vaccine advisory panel, US ...
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump administration vs. mRNA vaccines ...
BioNTech is buying fellow German mRNA vaccine developer CureVac in all-stock transaction that values the acquired biotech at ...